Determining Dosing For IV Or Subcutaneous Delivery

Why It Matters

Choosing the optimal delivery route directly impacts patient adherence, healthcare costs, and market competitiveness for new therapeutics.

Key Takeaways

• Stability dictates feasibility of subcutaneous formulation
• Bioavailability varies significantly between IV and SC
• Administration frequency influences patient adherence
• Patient convenience drives preference for subcutaneous
• Regulatory pathways differ for IV versus SC products

Pulse Analysis

The decision to formulate a drug for intravenous versus subcutaneous administration begins with a deep dive into the molecule’s physicochemical properties. Stability in aqueous solution, viscosity, and aggregation propensity determine whether a biologic can be concentrated enough for a subcutaneous injection without compromising efficacy. Formulators must also consider the drug’s bioavailability; while IV offers 100% systemic exposure, subcutaneous routes introduce absorption variability that can affect dosing schedules and therapeutic windows. By leveraging advanced excipients and delivery technologies, developers can mitigate these challenges, enabling higher-concentration formulations that maintain patient safety.

Beyond the science, patient centricity has become a strategic imperative in drug development. Frequent clinic‑based IV infusions can strain healthcare resources and diminish quality of life, especially for chronic conditions. Subcutaneous delivery, often administered at home, reduces travel burdens, lowers infusion‑center costs, and improves adherence rates. Companies that successfully transition therapies from IV to SC can differentiate themselves in competitive markets, capture premium pricing, and accelerate market uptake. This shift also aligns with payer expectations for cost‑effective, outpatient treatment models.

Regulatory considerations further shape the IV versus SC choice. Subcutaneous products typically require robust immunogenicity and local tolerability data, while IV products must demonstrate consistent infusion safety. Early engagement with agencies can streamline the approval pathway, ensuring that formulation decisions align with both clinical objectives and commercial timelines. As the industry embraces patient‑focused drug delivery, the nuanced balance of scientific, operational, and regulatory factors will dictate the next generation of biologics, making formulation strategy a critical lever for success.

Original Description

In this segment of the Drug Delivery Leader Live online event, Injected, Infused, or Implanted: A Penetrating Look At Patient Centricity, Chief Editor Tom von Gunden asks panelist Beate Bittner to describe early-stage formulation considerations from a patient dosing perspective. Bittner illuminates factors influencing decisions around IV versus subcutaneous administration.

See more at https://www.drugdeliveryleader.com/